"reported a strong association between expression of TMPRSS2 fusion with members of the ETS family of genes and PCa aggressiveness , and the interest about TMPRSS2 : ERG fusion protein was increasingly growing . However , more recent studies reported conflicting results about the role of such chromosomal rearrangement and a recent meta - analysis ( Pettersson et al . 2012 ) concluded that TMPRSS2 : ERG expression is associated with tumor stage but is a weak parameter in predicting recurrence or mortal - ity . In accordance with such conclusion and with previous studies of our group ( Bonaccorsi et al . 2009 ) , we show here that mRNA expression of TMPRSS2 : ERG fusion gene in FFPE needle biopsy specimens"
[Show abstract][Hide abstract] ABSTRACT: To evaluate biomarkers involved in biological pathways for prostate cancer (PCa) progression, measured in biopsy specimens, in order to distinguish patients at higher risk for fatal PCa and thus improve the initial management of disease.
Retrospective case-control study. In 129 PCa patients who underwent ultrasound-guided needle prostate biopsy and subsequent radical prostatectomy from 1987 to 1999 at the University Hospital of Careggi, we evaluated: (1) mRNA expression of the serine 2 (TMPRSS2): erythroblastosis virus E26 oncogene homolog (ERG); (2) expression of matrix metalloproteinases (MMP)-2 and 9 (epithelial and stromal); (3) expression of androgen receptor; (4) expression of prognostic marker Ki67 (MIB1); (5) presence and typing of human papilloma virus; (6) DNA methylation of CpG islands of several genes involved in PCa progression.
The cohort consists of 38 cases (patients with PCa and died of PCa within 10 years from diagnosis) and 91 controls (patients with PCa but alive 10 years after diagnosis). Gleason bioptic score, epithelial MMP expression and SERPINB5 methylation correlated with statistically significant increase in death risk OR. Compared with patients with high level of MMP, patients with low level of MMP had OR for specific death 4.78 times higher (p = 0.0066). After adjustment for age and Gleason score, none of the investigated biomarkers showed increased OR for PCa death.
Our preliminary results suggest that evaluation, in prostate biopsy specimens, of a panel of biomarkers known to be involved in PCa progression is poorly indicative of tumor outcome.
Journal of Cancer Research and Clinical Oncology 07/2015; DOI:10.1007/s00432-015-2015-1 · 3.08 Impact Factor
"Lin et al. recently reported that TMPRSS2-ERG levels in post-DRE urine were associated with higher tumour volume and GS in subsequent biopsies , and data indicate that high values of TMPRSS2-ERG fusion mRNA in expressed prostatic secretion are associated with an increased risk of tumour upgrading and upstaging in AS candidates undergoing immediate RP . This apparent prognostic difference between gene-fusion positivity and negativity in untreated patients has not, however, been found translated into a risk of postsurgical biochemical recurrence  . This discrepancy may be explained by differences between the cohorts, pathologic specimens, clinical end points, ERG-fusion detection methods , and tumour multifocality . "
[Show abstract][Hide abstract] ABSTRACT: Background
Compelling biomarkers identifying prostate cancer patients with a high risk of progression during active surveillance (AS) are needed.
To examine the association between ERG expression at diagnosis and the risk of progression during AS.
Design, setting, and participants
This study included 265 patients followed on AS with prostate-specific antigen (PSA) measurements, clinical examinations, and 10–12 core rebiopsies from 2002 to 2012 in a prospectively maintained database. ERG immunohistochemical staining was performed on diagnostic paraffin-embedded formalin-fixed sections with a ready-to-use kit (anti-ERG, EPR3864). Men were characterised as ERG positive if a minimum of one tumour focus demonstrated ERG expression.
Outcome measurements and statistical analysis
Overall AS progression was defined as clinical progression: increased clinical tumour category ≥cT2b by digital rectal examination and ultrasound, and/or histopathologic progression: upgrade of Gleason score, more than three positive cores or bilateral positive cores, and/or PSA progression: PSA doubling time <3 yr. Risk of progression was analysed using multiple cause-specific Cox regression and stratified cumulative incidences (Aalen-Johansen method). Curatively intended treatment, watchful waiting, and death without progression were treated as competing events.
Results and limitations
A total of 121 of 142 ERG-negative and 96 of 123 ERG-positive patients had complete diagnostic information. In competing risk models, the ERG-positive group showed significantly higher incidences of overall AS progression (p < 0.0001) and of the subgroups PSA progression (p < 0.0001) and histopathologic progression (p < 0.0001). The 2-yr cumulative incidence of overall AS progression was 21.7% (95% confidence interval [CI], 14.3–29.1) in the ERG-negative group compared with 58.6% (95% CI, 48.7–68.5) in the ERG-positive group. ERG positivity was a significant predictor of overall AS progression in multiple Cox regression (hazard ratio: 2.45; 95% CI, 1.62–3.72; p < 0.0001). The main limitation of this study is its observational nature.
In our study, ERG positivity at diagnosis can be used to estimate the risk of progression during AS. If confirmed, ERG status can be used to individualise AS programmes.
The tissue biomarker ERG identifies active surveillance patients with an increased risk of disease progression.
European Urology 11/2014; 66(5). DOI:10.1016/j.eururo.2014.02.058 · 13.94 Impact Factor
"Since TMPRSS2-ERG fusion first reported by Tomlins and colleagues in 2005, its role in PCa oncogenesis, PCa diagnosis and prognosis have been extensively studied. It is widely accepted that TMPRSS2-ERG fusion is PCa specific  and can be used to subtype and stratify PCa    . However, due to the relative low sensitivity, the value of TMPRSS2-ERG fusion as a PCa diagnostic marker is limited. "
[Show abstract][Hide abstract] ABSTRACT: Erythroblastosis virus E26 related gene (ERG) overexpression is correlated with the TMPRSS2-ERG fusion gene, a rearrangement known to be present in about 50% of cases of prostate cancer. Androgen receptor (AR) is a known regulator of the TMPRSS2 gene. Despite knowledge of this relationship, limited data is available on the specific relationship of AR expression to TMPRSS2-ERG fusion (ERG) status in prostate cancer (PCa). We used multiplexed immunohistochemistry, multispectral imaging technology and tissue microarray (TMA) to elucidate this relationship. Two prostate tissue microarrays were created from two cohorts of hormonal naïve patients’ prostatectomy specimens: progression TMA (pTMA, from 95 PCa patients) and outcome TMA (oTMA, from 183 PCa patients with at least 5-year follow-up information). Each of the two TMAs were triple-stained with ERG, AR and E-cadherin antibodies and visualized with a different chromogen. We found marked difference in AR expression levels between ERG positive (ERG+) and ERG negative (ERG-) prostate cancer. The difference was significant in localized (pT2) prostate cancer. We also found that AR expression levels were significantly higher in PCa tissue compared to benign prostate tissue, with the highest expression levels in ERG+ metastatic cancer. Neither AR nor ERG expression was associated with clinical outcome. Our findings confirm that TMPRSS2-ERG fusion is AR-dependent and is associated with increased AR expression. Our data suggest that the AR pathway may play an important role in the development of ERG+ PCa and ERG status may be useful in stratifying PCa patients for hormonal therapy.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.